Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the β-catenin/TCF complex association via FOXO3a activation

Doxorubicin is a conventional and effective chemotherapy drug against hepatocellular carcinoma (HCC). However, during long-term doxorubicin monotherapy, HCC cells may eventually develop acquired-resistance to doxorubicin which results in recurrence and a poor prognosis. Salinomycin, an ionophore ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Yue, Liang, Chao, Xue, Fei, Chen, Wei, Zhi, Xiao, Feng, Xinhua, Bai, Xueli, Liang, Tingbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496360/
https://www.ncbi.nlm.nih.gov/pubmed/25871400

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496360/
https://www.ncbi.nlm.nih.gov/pubmed/25871400

Ejemplares similares